EverPoint Asset Management’s Akebia Therapeutics AKBA Stock Holding History

EverPoint Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-200,000	Closed	-$1.5M	–	405
2016 Q2	$1.5M	Sell	200,000 -150,000	-43%	-$1.31M	0.03%	339
2016 Q1	$3.15M	Buy	+350,000	New	+$2.84M	0.06%	287

Other funds holding AKBA

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

EverPoint Asset Management's AKBA Position: Q3 2016 in Review

EverPoint Asset Management sold out of Akebia Therapeutics (AKBA) in Q3 2016, closing a stake of 200,000 shares — an estimated $1.5M sold.

EverPoint Asset Management first reported a position in AKBA in Q1 2016 and held it in 2 quarters. The position peaked at $3.15M in Q1 2016. 87 funds tracked by Wall St. Rank hold AKBA as of Q3 2016.

EverPoint Asset Management reported no remaining Akebia Therapeutics position as of Q3 2016 after selling out during the quarter.
EverPoint Asset Management sold 200,000 Akebia Therapeutics shares in Q3 2016, an estimated $1.5M.
EverPoint Asset Management first reported a position in Akebia Therapeutics in Q1 2016 and held it in 2 quarters.
EverPoint Asset Management's Akebia Therapeutics position peaked at $3.15M in Q1 2016.
87 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2016.

Based on EverPoint Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.